FDA issues nationwide recall of blood pressure medication bottles
Juste les faits

FDA issues nationwide recall of blood pressure medication bottles

Résumé

The U.S. Food and Drug Administration has recalled over 3,700 bottles of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets after quality testing showed they did not dissolve properly.

The U.S. Food and Drug Administration is urging consumers to inspect their medicine cabinets following a nationwide recall of blood-pressure medication bottles. The recall targets specific lots of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets produced by New Jersey-based Macleods Pharma USA.

The FDA announced the recall on Oct. 7, 2026, and later classified it as a Class II recall on Oct. 26, 2026, indicating that use of the affected medication could cause temporary or medically reversible health issues.

The recall includes 3,528 bottles containing 30 tablets each from lot 12251163A and 216 bottles containing 90 tablets each from lot 12251163B, both bearing an expiration date of May 31, 2027.

According to an FDA enforcement report, the tablets failed to meet quality standards because they did not dissolve as required during testing.

Source

WCVB

Continuez à lire — gratuitement

Créez un compte gratuit pour suivre l'actualité. Aucune carte requise.